1. India Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Anthem Biosciences Limited

Anthem Biosciences Limited

811.20
INR
+9.40
(+1.17%)
10.15EPS
75.15P/E
433.83BMarket Cap
Dec 02Next Earn
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
22.06
18.82
25.27
32.84
37.86
35.62
Basic EPS, GAAP
7.26
6.86
6.54
8.04
10.55
10.25
Free Cash Flow per Basic Share
3.08
1.98
-2.8
0.16
11.29
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
24.13
30.99
34.27
42.91
54.16
- -
Tangible Book Value per Share
24
30.83
34.16
42.84
54.16
- -
Basic Weighted Avg Shares
558
562
562
562
561
562
Sales/Revenue/Turnover
12,313
10,569
14,194
18,446
21,243
20,023
Operating Margin (%)
42.16
35.17
29.92
32.1
33.2
32.73
Depreciation Expense
578
638
818
894
1,341
1,376
Net Income, GAAP
4,055
3,852
3,673
4,513
5,918
5,759
Effective Tax Rate (%)
25.74
22.54
23.05
31.3
28.2
26.4
Profit Margin (%)
32.94
36.44
25.88
24.46
27.86
28.76
Working Capital
8,671
11,593
11,429
11,619
14,774
- -
LT Debt
70
970
1,160
499
286
- -
Total Equity
13,550
17,407
19,247
24,099
30,425
- -
Return on Invested Capital (%)
- -
20.44
16.15
17.12
17.11
- -
Return on Capital (%)
- -
24.02
18.58
19.55
21.23
- -
Return on Common Equity (%)
- -
24.89
20.04
20.82
21.71
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
253
- -
LT Borrowings
- -
277
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
562
562
563
Market Capitalization
365,636
368,653
433,834

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
18,031
- -
Cash, Cash Equivalents & STI
- -
9,385
- -
Accounts Receivable, Net
- -
5,906
- -
Inventories
- -
1,245
- -
Total Current Liabilities
- -
3,257
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
253
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
26.25%
Free Cash Flow
- -
- -
6,781.63%
Net Income, GAAP
- -
- -
31.14%
Sales/Revenue/Turnover
- -
- -
15.17%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
5,250
4,978
4,832
18,446
2026
5,402
5,500
4,232
6,109
21,243
2027
4,182
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
2.9
2.22
1.48
8.04
2026
2.42
3.09
1.65
3.38
10.55
2027
2.13
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ajay Bharadwaj
Full Time Employees
3,302
Sector
Health technology
Industry
Biotechnology
Address
No. 49, F1 & F2, Canara Bank Road Bangalore KA India 560099
IPO Date
Jul 21, 2025
Website
anthembio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Anthem Biosciences Ltd. (ANTHEM.NS) operates as an innovation-driven, technology-focused contract research, development, and manufacturing organization (CRDMO) with fully integrated operations spanning drug discovery, development, and commercial manufacturing across New Chemical Entity (NCE) and New Biological Entity (NBE) programs. The company provides end-to-end services including medicinal chemistry, preclinical research, in vitro and in vivo testing, process development, clone development, antibody-drug conjugates, RNA interference platforms, peptides, lipids, oligonucleotides, GMP synthesis from milligram to multi-ton scale, quality control, analytical development, stability studies, and regulatory support; it also manufactures and sells specialty ingredients such as active pharmaceutical ingredients (APIs) like Cabergoline, Calcium Folinate, L-Methyl Tetrahydrofolate Calcium, Ormeloxifene, Pancreatin, Papain, Pyridoxal-5-Phosphate, Serratiopeptidase, Valganciclovir, and Voglibose, alongside nutraceuticals for human nutrition (e.g., Alpha GPC, Resveratrol, probiotics including Bacillus clausii and Lactobacillus rhamnosus), enzymes (e.g., Alpha Galactosidase, Amylase), animal nutrition products, and industrial applications in food, feed, textiles, and biofuels. Anthem serves a diverse global customer base of over 150 clients, including emerging biotech firms, small to mid-sized pharmaceutical companies, and large innovator pharma, with a focus on high-growth areas like GLP-1 agonists (e.g., Semaglutide, Liraglutide), anti-infectives, and biosimilars; operations span the United States (89 customers via partnerships), Europe, Japan, and other regions, supported by cGMP facilities inspected by USFDA, PMDA, and EU QPs. Founded in 2006 and headquartered in Bengaluru, India, at No. 49, Canara Bank Road, Electronics City Phase 1, the company completed India's largest CRDMO initial public offering (IPO) in July 2025, achieving the highest revenue growth from fiscal 2024 to 2025 among peers, and maintains a strategic U.S. sales partnership with DavosPharma (an affiliate of shareholder Portsmouth LLC) to onboard emerging biotech customers; its pipeline includes 242 projects (68 in discovery, 145 in early development, 16 in late-stage) as of March 31, 2025.